File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.talanta.2017.09.092
- Scopus: eid_2-s2.0-85031997612
- PMID: 29136901
- WOS: WOS:000416615500109
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Biomarker analysis of hemoglobin adducts of acrylamide and glycidamide enantiomers for mid-term internal exposure assessment by isotope dilution ultra-high performance liquid chromatography tandem mass spectrometry
Title | Biomarker analysis of hemoglobin adducts of acrylamide and glycidamide enantiomers for mid-term internal exposure assessment by isotope dilution ultra-high performance liquid chromatography tandem mass spectrometry |
---|---|
Authors | |
Keywords | Acrylamide Biomarker Enantiomers Glycidamide Hemoglobin adducts Internal exposure |
Issue Date | 2018 |
Citation | Talanta, 2018, v. 178, p. 825-833 How to Cite? |
Abstract | Hemoglobin (Hb) adducts of acrylamide (AA) and its oxidative metabolite glycidamide (GA) are important biomarkers for evaluating the mid-term exposure of acrylamide toxicity in vivo. Taking pentafluoro-2-methylphenyl isothiocyanates of N-(2-carbamoylethyl)valine (AAVal-PFPTH) and N-(2-carbamoyl-2-hydroxyethy)valine (GAVal-PFPTH) as target analytes, we developed an isotope dilution ultra-high performance liquid chromatograph tandem mass spectrometry (UHPLC-MS/MS) method for the simultaneous determination of AA and GA hemoglobin (Hb) adducts under the electroscopy ionization negative (ESI‾) mode in the present work. Among them, the enantiomer pair of GA-Hb adducts was firstly identified and successfully separated at baseline level. The method achieved high sensitivity with the LOD and LOQ ranging 1.43–5.05 pmol/g Hb and 4.78–16.82 pmol/g Hb, respectively. The recovery rates with low, intermediate and high spiking levels were calculated as 97.0–105.2%, 97.4–106.4% and 100.3–111.2%, respectively. Acceptable within-laboratory reproducibility (RSD < 13.7%) substantially supported the robustness of current UHPLC-MS/MS method, which was successfully applied to measure the hemoglobin adducts of acrylamide and glycidamide enantiomers in blood of both rats and humans. A linear exposure assessment model was developed for estimating the daily exposure to acrylamide in humans via considering acrylamide hemoglobin adducts as variables, indicating a novel connect between biomarker-based internal exposure and dietary-based external exposure. Overall, the present instrumental analysis and related internal exposure assessment model provide a substantially methodological support for profiling the internal biological exposure and estimating the external dietary exposure to acrylamide. |
Persistent Identifier | http://hdl.handle.net/10722/342550 |
ISSN | 2023 Impact Factor: 5.6 2023 SCImago Journal Rankings: 0.956 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang, Yu | - |
dc.contributor.author | Wang, Qiao | - |
dc.contributor.author | Zhang, Gong | - |
dc.contributor.author | Jia, Wei | - |
dc.contributor.author | Ren, Yiping | - |
dc.contributor.author | Wu, Yongning | - |
dc.date.accessioned | 2024-04-17T07:04:36Z | - |
dc.date.available | 2024-04-17T07:04:36Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Talanta, 2018, v. 178, p. 825-833 | - |
dc.identifier.issn | 0039-9140 | - |
dc.identifier.uri | http://hdl.handle.net/10722/342550 | - |
dc.description.abstract | Hemoglobin (Hb) adducts of acrylamide (AA) and its oxidative metabolite glycidamide (GA) are important biomarkers for evaluating the mid-term exposure of acrylamide toxicity in vivo. Taking pentafluoro-2-methylphenyl isothiocyanates of N-(2-carbamoylethyl)valine (AAVal-PFPTH) and N-(2-carbamoyl-2-hydroxyethy)valine (GAVal-PFPTH) as target analytes, we developed an isotope dilution ultra-high performance liquid chromatograph tandem mass spectrometry (UHPLC-MS/MS) method for the simultaneous determination of AA and GA hemoglobin (Hb) adducts under the electroscopy ionization negative (ESI‾) mode in the present work. Among them, the enantiomer pair of GA-Hb adducts was firstly identified and successfully separated at baseline level. The method achieved high sensitivity with the LOD and LOQ ranging 1.43–5.05 pmol/g Hb and 4.78–16.82 pmol/g Hb, respectively. The recovery rates with low, intermediate and high spiking levels were calculated as 97.0–105.2%, 97.4–106.4% and 100.3–111.2%, respectively. Acceptable within-laboratory reproducibility (RSD < 13.7%) substantially supported the robustness of current UHPLC-MS/MS method, which was successfully applied to measure the hemoglobin adducts of acrylamide and glycidamide enantiomers in blood of both rats and humans. A linear exposure assessment model was developed for estimating the daily exposure to acrylamide in humans via considering acrylamide hemoglobin adducts as variables, indicating a novel connect between biomarker-based internal exposure and dietary-based external exposure. Overall, the present instrumental analysis and related internal exposure assessment model provide a substantially methodological support for profiling the internal biological exposure and estimating the external dietary exposure to acrylamide. | - |
dc.language | eng | - |
dc.relation.ispartof | Talanta | - |
dc.subject | Acrylamide | - |
dc.subject | Biomarker | - |
dc.subject | Enantiomers | - |
dc.subject | Glycidamide | - |
dc.subject | Hemoglobin adducts | - |
dc.subject | Internal exposure | - |
dc.title | Biomarker analysis of hemoglobin adducts of acrylamide and glycidamide enantiomers for mid-term internal exposure assessment by isotope dilution ultra-high performance liquid chromatography tandem mass spectrometry | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.talanta.2017.09.092 | - |
dc.identifier.pmid | 29136901 | - |
dc.identifier.scopus | eid_2-s2.0-85031997612 | - |
dc.identifier.volume | 178 | - |
dc.identifier.spage | 825 | - |
dc.identifier.epage | 833 | - |
dc.identifier.isi | WOS:000416615500109 | - |